Clinical Trial Update: A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients [Phase 2]

View source ↗

Summary

A Phase II clinical trial is evaluating HLX22 in combination with trastuzumab deruxtecan for HER2-low, hormone receptor-positive breast cancer and is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Low Breast Cancer

Drugs mentioned

• HLX22
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: HER2-low Hormone Receptor Positive Breast Cancer | Phase 2 | Status: RECRUITING